Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables (2016 - 2025)

Ascendis Pharma A's Receivables history spans 8 years, with the latest figure at $59.1 million for Q4 2023.

  • For Q4 2023, Receivables rose 134.3% year-over-year to $59.1 million; the TTM value through Dec 2023 reached $59.1 million, up 134.3%, while the annual FY2023 figure was $59.5 million, 128.02% up from the prior year.
  • Receivables for Q4 2023 was $59.1 million at Ascendis Pharma A, up from $25.2 million in the prior quarter.
  • Across five years, Receivables topped out at $59.1 million in Q4 2023 and bottomed at $6.0 million in Q4 2019.
  • The 5-year median for Receivables is $25.2 million (2022), against an average of $24.9 million.
  • The largest annual shift saw Receivables skyrocketed 194.74% in 2019 before it dropped 1.01% in 2022.
  • A 5-year view of Receivables shows it stood at $6.0 million in 2019, then skyrocketed by 46.14% to $8.8 million in 2020, then skyrocketed by 191.25% to $25.5 million in 2021, then fell by 1.01% to $25.2 million in 2022, then soared by 134.3% to $59.1 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Receivables are $59.1 million (Q4 2023), $25.2 million (Q4 2022), and $25.5 million (Q4 2021).